Thread - two bits of news:
1. NEW YORK, Nov 14, 2000 /PRNewswire via COMTEX/ -- The European Patent Office (EPO) revoked in its entirety a patent issued to StressGen Biotechnologies Corp. relating to the use of heat shock proteins (HSPs) for the treatment of cancer and infectious diseases. Antigenics (Nasdaq: AGEN chart, msgs) filed an opposition to the StressGen patent in June 1996 on grounds that the patent was invalid. After Antigenics filed its opposition, StressGen amended the claims to exclude patient-specific treatment of cancer. The EPO issued a preliminary ruling in June 1998 that the patent should be revoked. In response, StressGen further amended the patent. The amended patent was finally revoked at today's hearing in Munich, Germany.
[snip]
2. NEW YORK, Nov 17, 2000 /PRNewswire via COMTEX/ -- Antigenics Inc. (Nasdaq: AGEN chart, msgs) announced today that it has completed its previously announced merger with Aquila Biopharmaceuticals, Inc. (Nasdaq: AQLA chart, msgs) effective as of the close of trading on November 16. Aquila shareholders voted to approve the merger on November 15. Aquila will now operate as a wholly-owned subsidiary of Antigenics. In connection with the merger, Antigenics will issue approximately 2.5 million shares of common stock, based on an exchange ratio of 0.2898 shares of Antigenics stock for each share of Aquila stock.
[snip]
Robertson-Stevens had some nice things to say about AGEN, too.
Regards,
Harry |
